Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.

You may also be interested in...

Genocea Gets An Injection Of Capital As Early-Stage Studies Progress

The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.

Hepatitis C, HIV, Antibiotics And Vaccines Headline Infectious Diseases Discussion At TAP Conference

In developing the infectious diseases track for this year’s Therapeutic Area Partnerships conference, planners focused on areas of unmet medical need, market potential, companies with a diversity of indications, strong science and multi-level partnering opportunities.

13 Going On 50: Pfizer Seeks Adult Indication For Prevnar

Advisory committee might closely scrutinize the requested indication for the 13-valent pneumococcal conjugate vaccine for adults age 50 and up; it is now indicated for children under six years old.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts